This publication strengthens the clinical validation for ALXN1840, a late-stage asset in a rare disease with clear unmet need. Watch for upcoming regulatory interactions (NDA/ MAA filing) and any partnership/licensing discussions that could crystallize value. The stock's $377M market cap leaves upside potential if ALXN1840 advances toward approval in Wilson disease.
Price Chart
Executive Summary
Monopar announced the peer-reviewed publication of Phase 2 study results in Hepatology Communications demonstrating that ALXN1840 produces a rapid, statistically significant, and sustained improvement in daily copper balance in patients with Wilson disease. The cumulative mean decrease in copper balance was -6.08 mg over 21 days (p=0.005), and ALXN1840 was generally well tolerated with no serious adverse events. This validates the drug's mechanism and supports regulatory and commercial prospects for ALXN1840 in Wilson disease, reinforcing the asset's late-stage clinical profile.
Key Facts
- Phase 2 ALXN1840-WD-204 study published in Hepatology Communications, a peer-reviewed journal.
- Cumulative mean decrease in copper balance of -6.08 mg over 21 days (95% CI: -10.18 mg to -1.98 mg).
- Mean daily copper balance change from baseline of -0.37 mg (p=0.005) during 15 mg/day period and -0.29 mg (p=0.023) overall.
- Approximately 50% increase in daily fecal copper output-to-intake ratio vs baseline (p=0.041).
- Improvements seen in patients with mean prior standard-of-care treatment duration of 16 years.
- ALXN1840 was generally well tolerated; no serious adverse events reported.
- Phase 3 trial previously demonstrated superior copper mobilization vs standard of care over 48 weeks.
Financial Impact
No financial data reported in this filing. Publication milestone supports the ongoing regulatory and commercial pathway for ALXN1840.
Risk Factors
- Regulatory timeline and outcome for ALXN1840 remain uncertain; no filing date announced.
- Phase 2 study was open-label, single-arm with only 9 patients — limited sample size.
- Company is pre-revenue and will need additional financing to fund regulatory and commercial launch activities.
- Competitive landscape includes existing standard-of-care therapies for Wilson disease.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-017821 |
| Exhibit: ex_962026.htm | 0001437749-26-017821 |
| Document: 0001437749-26-017821-index-headers.html | 0001437749-26-017821 |
| Document: 0001437749-26-017821-index.html | 0001437749-26-017821 |
| Document: 0001437749-26-017821.txt | 0001437749-26-017821 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 21d ago | Insider Cluster | $79.57 | awaiting T+60 | — | $70.54 (+11.35%) |
Oct 1, 2026 25d ago | 144 | $77.97 | awaiting T+60 | — | $70.54 (−9.53%) |
Aug 28, 2026 8w ago | Insider Cluster | $111.93 | awaiting T+60 | — | $70.54 (−36.98%) |
Aug 27, 2026 8w ago | Insider Cluster | $111.89 | awaiting T+60 | — | $70.54 (−36.96%) |
Aug 25, 2026 8w ago | 144 | $113.72 | awaiting T+60 | — | $70.54 (−37.97%) |
Aug 12, 2026 10w ago | 8-K | $114.90 | awaiting T+60 | — | $70.54 (−38.61%) |
Aug 12, 2026 10w ago | Press Release | $114.90 | awaiting T+60 | — | $70.54 (−38.61%) |
Jul 22, 2026 13w ago | 8-K | $112.48 $71.80 | ▼ −36.17% | ▼ −39.43% | $70.54 (−37.29%) |
Jul 22, 2026 13w ago | Press Release | $112.48 $71.80 | ▼ −36.17% | ▼ −39.43% | $70.54 (−37.29%) |
Jun 30, 2026 16w ago | 8-K | $92.59 $89.38 | ▼ −3.47% | ▼ −7.03% | $70.54 (−23.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers